The effect of endostatin and gemcitabine combined with HIFU on the animal xenograft model of human pancreatic cancer.
OBJECTIVE
To investigate the influence of the recombinant human endostatin and gemcitabine combined with HIFU on the mouse xenograft model of pancreatic cancer.


METHODS
Use human pancreatic cancer cell line PANC-1 to set up the mouse xenograft model, then randomized into four arms. Each arm was treated with gemcitabine, endostatin, gemcitabine combined with endostatin and normal saline respectively. Observe the volume of the tumor, the serum VEGF level and MVD in the tumor tissue among the different arms. All mice were treated with HIFU, then pathological examination was done.


RESULTS
The tumor volume, serum VEGF level and MVD in the combined-therapy arm are all lower than the monotherapy arms and the control arm. The coagulation necrosis occurred in tumors after HIFU treatment.


CONCLUSIONS
Endostatin and gemcitabine has better effect than gemcitabine or endostatin monotherapy on the animal xenograft model of human pancreatic cancer. HIFU combined with chemotherapy and/or targeted therapy may enhance the effect for pancreatic cancer.
Wang
Rong-sheng
RS
Cancer Center, The First Affiliated Hospital of Nanjing Medical University, 300, Guangzhou Road, Nanjing 210029, China.
Liu
Ling-xiang
LX
Gu
Yan-hong
YH
Lin
Qing-feng
QF
Guo
Ren-hua
RH
Shu
Yong-qian
YQ
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D016503:Drug Delivery Systems; D043169:Endostatins / Q000008:administration & dosage; D005260:Female; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D055806:Microvessels / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000628:therapy*; D011897:Random Allocation; D014464:Ultrasonic Therapy / Q000379:methods*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood; D023041:Xenograft Model Antitumor Assays; D000093542:Gemcitabine
D043169:Endostatins; D042461:Vascular Endothelial Growth Factor A; D003841:Deoxycytidine; D000093542:Gemcitabine